OBJECTIVE: The attempt to improve therapeutic results in @entity3123 has recently focused on the emerging role of molecular biology. We investigated the role of @entity2247 and NF-KB expression in relation to the use of a @entity2247 inhibitor ( @entity12698 ) associated to @entity136 and @entity901 in @entity788 . METHODS: Forty-four @entity1 with histologically or cytologically verified, locally advanced unresectable and/or metastatic @entity3123 were eligible for the study. RESULTS: Thirty-three @entity1 (75%) assumed @entity12698 for all their treatment period. Treatment was repeated every 2 weeks, until there was evidence of disease progression, @entity1 refusal, or unacceptable @entity137 . Efficacy was assessed according to @entity5 response, clinical benefit, and time-related parameters. Five @entity1 had a partial response, 24 had a stable disease, and 15 had a disease progression, for an overall response rate of 11%. Biochemical response rate based on CA 19.9 levels showed 2 complete and 10 partial responses, whereas 31 @entity1 presented no changes of CA 19.9 levels. @entity2247 protein expression was found in 30 @entity5 , while a moderate or weak/absent expression was present in 10 @entity1 . Sixteen @entity5 showed a strong expression for NF-KB, 4 a moderate expression, and 5 a weak/absent expression. CONCLUSION: The use of a @entity2247 inhibitor does not add any valuable activity to a @entity136 / @entity901 combination, even in @entity1 with @entity2247 and NF-KB overexpressing @entity5 .

XXXX and NF-KB overexpression is common in @entity788 but does not predict for @entity2247 inhibitors activity in combination with @entity136 and @entity901 .

@entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity3123 :: ('MESH:C562463', 'Disease') :: ['pancreatic carcinoma'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer'] @entity12698 :: ('MESH:C105934', 'Chemical') :: ['celecoxib'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity2247 :: ('4513', 'Gene') :: ['COX-2'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity2247 :: (4513,Gene) :: ['COX-2']
